33
Participants
Start Date
November 30, 2015
Primary Completion Date
December 13, 2017
Study Completion Date
December 13, 2017
Tisotumab vedotin (HuMax-TF-ADC)
Institut Jules Bordet, Brussels
Semmelweis Egyetem Onkológiai Központ, Budapest
Cliniques Universitaires Saint-Luc, Brussels
Universitaire Ziekenhuizen Leuven, Leuven
CHU de Liège, Liège
Debreceni Egyetem Klinikai Központ, Debrecen
CHU UCL Namur - Sainte Elisabeth, Namur
CHU UCL Namur - site Godinne, Yvoir
Grand Hôpital de Charleroi, Charleroi
Petz Aladár Megyei Oktató Kórház, Győr
MD Anderson Cancer Center, Houston
Rigshospitalet, Copenhagen University Hospital, Copenhagen
University College London Hospitals NHS Foundation Trust, London
Sarah Cannon Cancer Center, London
The Christie NHS Foundation Trust, Manchester
The Royal Marsden NHS Foundation Trust, Sutton
Collaborators (1)
Genmab
INDUSTRY
Seagen Inc.
INDUSTRY